Topic

William Borden is a freelance journalist covering the pharmaceutical industry. He is based in New Jersey.

Articles

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition 

Former chief strategy officer, Novartis Pharmaceuticals Corporation

Head of access & BDL strategy, Novartis Pharmaceuticals Corporation

Principal, Leavitt Partners, an HMA Company

Director, Leavitt Partners, an HMA Company

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a Catch

Ford discusses how rising drug costs in impact patients, and how they can either avoid them or find less-expensive options.

Q&A With Paul Ford, co-founder and president, DS9 Capital

Bruce Liu is a partner at Simon-Kucher & Partners, leading its life sciences division in greater China.

Justinian Liu is a senior consultant for Simon-Kucher.

Selene Peng is a senior consultant for Simon-Kucher.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare

Senior Advisor to the FoCUS Project and Chief Clinical Officer for Real Endpoints

Upcoming regulatory changes to create new opportunity for specialized offerings.

Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and Patients

Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.

A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip 

Jill Wechsler is Pharm Exec's Washington Corespondent

As Congress struggles to reach agreement on funding for leading social and spending initiatives and to avoid default on government borrowing, the White House is emphasizing that reduced spending on prescription drugs can help offset some of the steep costs.

Drug Costs Central Issue in Budget Battles

The Democratic proposal to authorize price negotiations on costly medicines covered by Medicare and to penalize firms that raise prices faster than inflation has drawn opposition pharma and biotech companies. More surprisingly, generic companies also are objecting to the changes on the table.

Generics Makers Also Fight Price Controls

Bruce Liu leads Simon-Kucher’s Life Sciences division in Greater China. He has over 20 years of experience in the life sciences industry and is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.

Shiyi He is a consultant with extensive experience in health economics and payer strategies in China.

Ivy Jiang is a consultant with years of experience in China pharmaceutical pricing and access strategies.

Duo Xu is a consultant specialized in China pharma and healthcare industry with recent experience on NRDL renewals.

Selene Peng is a consultant with experience across diverse therapeutic areas, and recent experience on NRDL trends and outlook.

The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.


China 2021 National Reimbursement Drug List Outlook

Democratic leaders in the House and Senate appear to have reached a compromise on a relatively modest plan for controlling prices on certain prescription drugs.